文献速递乳腺乳腺X线

对比增强乳腺X线摄影联合Kaiser评分在数字乳腺断层摄影BI-RADS 4A病变临床决策中的价值

Value of contrast-enhanced mammography combined with the Kaiser score for clinical decision-making regarding tomosynthesis BI-RADS 4A lesions.
PubMed 文献 · Eur Radiol · 2022-05-31

本回顾性研究纳入2019年6月至2021年6月间109个数字乳腺断层摄影(DBT)BI-RADS 4A病变,评估对比增强乳腺X线摄影(CEM)联合Kaiser评分(KS)的诊断效能。CEM无强化病变降级为BI-RADS 3,有强化病变参照乳腺MRI的KS分类。CEM联合KS的AUC为0.880~0.906,特异度高于单纯CEM BI-RADS或超声(P<0.001),敏感度无差异(P>0.05),可能避免72(75.8%)至78(82.1%)例不必要的良性活检。

要点

  • DBT BI-RADS 4A病变中,CEM无强化可降级为BI-RADS 3。
  • CEM联合KS的AUC为0.880~0.906,特异度优于单纯BI-RADS或超声。
  • CEM联合KS可能避免75.8%~82.1%的不必要良性活检。

核心结论

  • CEM联合KS可能用于DBT BI-RADS 4A病变,大幅减少不必要的良性活检。

研究设计与样本

  • 回顾性研究,纳入106例患者的109个DBT BI-RADS 4A病变,时间范围为2019年6月至2021年6月;采用CEM联合KS评估,以ROC曲线分析诊断效能,两名阅片者评估并计算Cohen kappa系数。

诊断标准与关键数值

  • CEM无强化病变降级为BI-RADS 3;有强化病变参照乳腺MRI的KS分类;CEM联合KS的AUC为0.880~0.906;CEM联合KS特异度高于CEM联合BI-RADS或超声(P<0.001),敏感度无差异(P>0.05);KS的阅片者间一致性为中等(kappa=0.727)。

临床应用与阅片要点

  • 在DBT BI-RADS 4A病变中,CEM无强化可降级为BI-RADS 3;有强化病变可参照KS分类,以提高特异度并可能减少不必要的良性活检。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To investigate the diagnostic performance of contrast-enhanced mammography (CEM) combined with the Kaiser score (KS) in digital breast tomosynthesis (DBT) BI-RADS 4A lesions to potentially reduce unnecessary breast biopsies.

METHODS: This retrospective study evaluated 106 patients with 109 DBT BI-RADS 4A lesions from June 2019 to June 2021. For the absence of enhancement on CEM, the lesions were downgraded to BI-RADS 3. For lesions with enhancement, the readers were asked to classify all enhancing lesions referring to the KS for breast MRI. Receiver operating characteristic (ROC) curve analysis was used to evaluate the diagnostic performance. Two readers rated all cases and interreader agreement was assessed by Cohen's kappa coefficients.

RESULTS: There were ninety-five benign lesions and 14 malignant lesions. CEM combined with KS's accuracy, represented by the area under the curve (AUC), ranged between 0.880 and 0.906. The use of the KS improved the performance, with a significant difference relative to a single BI-RADS reading or US (p < 0.001). CEM with KS had higher specificity than CEM with BI-RADS or US (p < 0.001), without difference in sensitivity (p > 0.05). CEM combined with KS could have potentially obviated 72 (75.8%) to 78 (82.1%) unnecessary benign biopsies in 95 benign lesions previously DBT classified as BI-RADS 4A. The interreader agreement was substantial (kappa: 0.727) for KS.

CONCLUSIONS: CEM combined with KS may be used in DBT BI-RADS 4A lesions to substantially reduce unnecessary benign biopsies.

KEY POINTS: • CEM combined with the Kaiser scoring system shows high diagnostic performance for DBT BI-RADS 4A lesions. • The application of CEM combined with the Kaiser scoring system may avoid 75.8% to 82.1% of unnecessary benign breast biopsies. • CEM combined with the KS aids clinical decision-making in DBT BI-RADS 4A lesions.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Rong, Kang, Xue, et al. Value of contrast-enhanced mammography combined with the Kaiser score for clinical decision-making regarding tomosynthesis BI-RADS 4A lesions. Eur Radiol. 2022. PMID: 35639141. doi:10.1007/s00330-022-08810-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。